Ratings Jafron Biomedical Co.,Ltd.

Equities

300529

CNE100002995

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
27.49 ^CNY	-0.29%		-0.33%	+23.66%

May. 24	Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024	CI
Apr. 26	Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's profit outlook over the next few years is a strong asset.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
JAFRON BIOMEDICAL CO.,LTD.	+23.66%	2.94B	D+
ABBOTT LABORATORIES	-2.34%	187B	C+
MEDTRONIC PLC	+0.92%	110B	C
BECTON, DICKINSON AND COMPANY	-1.77%	69.54B	A
CENCORA, INC.	+14.21%	46.37B	B-
DEXCOM, INC.	-6.06%	46.05B	B-
HOYA CORPORATION	+7.97%	42.54B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+19.03%	30.72B	B
TERUMO CORPORATION	+17.70%	25.62B	A-
ZIMMER BIOMET HOLDINGS, INC.	-7.25%	23.32B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes